Rep. Lisa C. McClain Purchases Shares of Encompass Health Corporation (NYSE:EHC)

Key Points

• Representative Lisa C. McClain purchased shares of Encompass Health Corporation (NYSE:EHC) valued between $1,001 and $15,000 on July 22nd, according to a filing.
• Encompass Health recently declared a quarterly dividend of $0.19 per share, an increase from the previous $0.17, with a payout ratio of 13.31%.
• The company reported better-than-expected earnings, with a quarterly EPS of $1.40, surpassing analysts' estimates by $0.20 and showing a revenue increase of 12.0% year-over-year.

Representative Lisa C. McClain (R-Michigan) recently bought shares of Encompass Health Corporation NYSE: EHC. In a filing disclosed on August 13th, the Representative disclosed that they had bought between $1,001 and $15,000 in Encompass Health stock on July 22nd. The trade occurred in the Representative's "CHARLES SCHWAB BROKERAGE ACCOUNT 924" account.

Representative Lisa C. McClain also recently made the following trade(s):

• Sold $1,001 - $15,000 in shares of Autoliv NYSE: ALV on 8/4/2025.
• Sold $1,001 - $15,000 in shares of Amazon.com NASDAQ: AMZN on 8/4/2025.
• Sold $1,001 - $15,000 in shares of Applied Materials NASDAQ: AMAT on 8/4/2025.
• Sold $1,001 - $15,000 in shares of Arthur J. Gallagher & Co. NYSE: AJG on 8/4/2025.
• Sold $1,001 - $15,000 in shares of SAP NYSE: SAP on 7/22/2025.
• Purchased $1,001 - $15,000 in shares of XPO NYSE: XPO on 7/22/2025.
• Purchased $1,001 - $15,000 in shares of Lithia Motors NYSE: LAD on 7/22/2025.
• Sold $1,001 - $15,000 in shares of Sanofi NASDAQ: SNY on 7/22/2025.
• Sold $1,001 - $15,000 in shares of Waters NYSE: WAT on 7/22/2025.
• Purchased $1,001 - $15,000 in shares of Group 1 Automotive NYSE: GPI on 7/22/2025.

Encompass Health Price Performance

Shares of NYSE EHC traded up $1.0450 during mid-day trading on Wednesday, reaching $123.1850. The company's stock had a trading volume of 202,577 shares, compared to its average volume of 814,768. The stock has a 50-day moving average of $116.19 and a two-hundred day moving average of $109.87. The company has a debt-to-equity ratio of 0.76, a quick ratio of 1.06 and a current ratio of 1.06. The stock has a market capitalization of $12.41 billion, a P/E ratio of 24.11, a P/E/G ratio of 2.10 and a beta of 0.86. Encompass Health Corporation has a 1-year low of $87.85 and a 1-year high of $123.35.

Encompass Health (NYSE:EHC - Get Free Report) last released its quarterly earnings data on Monday, August 4th. The company reported $1.40 EPS for the quarter, beating analysts' consensus estimates of $1.20 by $0.20. The company had revenue of $1.46 billion during the quarter, compared to the consensus estimate of $1.43 billion. Encompass Health had a net margin of 9.22% and a return on equity of 17.83%. Encompass Health's quarterly revenue was up 12.0% on a year-over-year basis. During the same quarter in the prior year, the firm earned $1.11 EPS. Encompass Health has set its FY 2025 guidance at 5.120-5.340 EPS. On average, equities research analysts anticipate that Encompass Health Corporation will post 4.8 EPS for the current fiscal year.

Encompass Health Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, October 15th. Stockholders of record on Wednesday, October 1st will be issued a dividend of $0.19 per share. The ex-dividend date of this dividend is Wednesday, October 1st. This is a positive change from Encompass Health's previous quarterly dividend of $0.17. This represents a $0.76 dividend on an annualized basis and a dividend yield of 0.6%. Encompass Health's payout ratio is currently 14.87%.

Hedge Funds Weigh In On Encompass Health

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Invesco Ltd. raised its holdings in Encompass Health by 5.1% in the first quarter. Invesco Ltd. now owns 5,818,783 shares of the company's stock valued at $589,326,000 after acquiring an additional 282,532 shares in the last quarter. T. Rowe Price Investment Management Inc. raised its holdings in shares of Encompass Health by 25.6% in the 1st quarter. T. Rowe Price Investment Management Inc. now owns 2,080,918 shares of the company's stock valued at $210,756,000 after purchasing an additional 424,691 shares in the last quarter. Alliancebernstein L.P. lifted its position in shares of Encompass Health by 6.8% during the 2nd quarter. Alliancebernstein L.P. now owns 2,039,314 shares of the company's stock worth $250,081,000 after purchasing an additional 129,276 shares during the last quarter. Dimensional Fund Advisors LP grew its stake in shares of Encompass Health by 5.3% during the first quarter. Dimensional Fund Advisors LP now owns 1,871,581 shares of the company's stock worth $189,549,000 after purchasing an additional 93,992 shares in the last quarter. Finally, Price T Rowe Associates Inc. MD increased its holdings in Encompass Health by 13.1% in the first quarter. Price T Rowe Associates Inc. MD now owns 1,822,376 shares of the company's stock valued at $184,571,000 after buying an additional 211,707 shares during the last quarter. Hedge funds and other institutional investors own 97.25% of the company's stock.

Wall Street Analyst Weigh In

EHC has been the topic of a number of recent research reports. Truist Financial boosted their price objective on Encompass Health from $135.00 to $140.00 and gave the stock a "buy" rating in a research note on Thursday, August 14th. Barclays upped their price objective on shares of Encompass Health from $118.00 to $129.00 and gave the company an "overweight" rating in a report on Friday, April 25th. Royal Bank Of Canada lifted their target price on shares of Encompass Health from $110.00 to $125.00 and gave the stock an "outperform" rating in a research note on Monday, April 28th. Wall Street Zen cut shares of Encompass Health from a "strong-buy" rating to a "buy" rating in a research note on Friday, June 6th. Finally, UBS Group lifted their price target on shares of Encompass Health from $130.00 to $140.00 and gave the company a "buy" rating in a research report on Wednesday, August 6th. One investment analyst has rated the stock with a Strong Buy rating and six have given a Buy rating to the company's stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Buy" and an average price target of $134.00.

About Representative McClain

Lisa McClain (Republican Party) is a member of the U.S. House, representing Michigan's 9th Congressional District. She assumed office on January 3, 2023. Her current term ends on January 3, 2027. McClain (Republican Party) is running for re-election to the U.S. House to represent Michigan's 9th Congressional District. She declared candidacy for the 2026 election. Lisa McClain lives in Romeo, Michigan. McClain earned a bachelor's degree in business administration from Northwood University. Her career experience includes founding and working as the president of North End Support Team.

About Encompass Health

Encompass Health Corporation provides post-acute healthcare services in the United States and Puerto Rico. It owns and operates inpatient rehabilitation hospitals that provide medical, nursing, therapy, and ancillary services. The company provides specialized rehabilitative treatment on an inpatient basis to patients who have experienced physical or cognitive disabilities or injuries due to medical conditions, such as strokes, hip fractures, and various debilitating neurological conditions.